Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on November 13, 2026
Lilly breaks ground on $3.5 billion Pennsylvania plant
The facility is expected to make obesity medicines, including investigational retatrutide, and begin operating by 2031.
Today in brief
Eli Lilly began building a $3.5 billion manufacturing facility in the Lehigh Valley, Pennsylvania.12 Lilly expects the site to create about 850 jobs and support roughly 2,000 construction workers.12
Lilly’s plant is planned for newer injectable medicines
Lilly expects the facility to make newer obesity medicines, including retatrutide, which remains investigational and is in Phase 3 trials.12 The company expects the site to begin operating by 2031.1
Lilly says the facility will use machine learning, digitally integrated systems and advanced data analytics.2 The project is part of a broader U.S. manufacturing investment that Lilly puts at $50 billion since 2020.12
Also published
- Automating the journey from bench to bedside Pharmaceutical Processing World
- What 3 Principles Guide Merck's Biologics and ADC Capacity Placement? BioPharm International
- Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave GEN
- Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Design Drug Discovery and Development